Case reports
Our policy in this hospital has been to treat all patients presenting with acute myocardial infarction with thrombolytic agents unless they have important contraindications. In addition, all patients are given anticoagulant treatment with heparin, the first dose being within six hours after thrombolytic treatment. In cases 1-5 reported below warfarin was also given, with the first dose within 24 hours after admission. The table gives details of the cases.
Case I -A 62 year old woman developed exquisitely painful lower legs 48 hours after thrombolytic treatment for an acute inferior myocardial infarction. The skin of her lower legs showed widespread mottling and discoloration but her peripheral pulses were normal. Doppler studies of her legs and tests for autoantibodies and anticardiolipin antibodies showed no abnormalities, and her erythrocyte sedimentation rate was normal. Computed tomography of her legs did 
Introduction
The most important complications of thrombolytic treatment are due to haemorrhage'; this may be inevitable because a physiological haemostatic plug and an unwanted thrombus present the same substrate for thrombolytic agents. Reperfusion injury is another direct consequence of thrombolysis. We observed a third complication associated with disintegration of clots after treatment with anistreplase or streptokinase, and we report on seven patients who had severe symptoms due, we believe, to multiple emboli from the disintegration of pre-existing thrombus in the heart or large arteries.
with steroids was started and anticoagulation with warfarin continued. Determination of antistreptolysin 0 titre, hepatitis B antigen, rheumatoid factor, complement, cryoglobulins, and immunoglobulins and an autoantibody screen, protein electrophoresis, microscopic examination of urine, and serological testing for syphilis gave normal results. The concentration of circulating immune complexes was increased (60 mg/l; normal range <20 mg/l), and the peak erythrocyte sedimentation rate was only 30 mm in the first hour. The patient's rash and tenderness of his calves improved after steroid treatment, and he was discharged home. Two 
Discussion
The seven patients described all had serious complications that we believe were due to systemic embolisation from disintegration of a pre-existing clot. The diagnosis cannot readily be proved. We think it is important, however, to draw attention to a pattern of events that we have seen fairly frequently only in association with thrombolysis, and believe that our experience is relevant to decisions about selecting cases for this important treatment.
Our seven cases were noted during a period when 475 patients were given thrombolytic treatment, an incidence of 1-5%. Multiple emboli from disintegration of the clot may therefore be an important, though fairly uncommon, complication.
We have no reason to believe that any one thrombolytic agent is more likely than others to cause this problem. Six cases occurred after anistreplase treatment and one after streptokinase. This ratio probably reflects our differential use of the two drugs over the period in question. The presence of fresh clot rather than organised clot is probably the most important determinant of risk. Care in selecting cases should reduce the incidence of microemboli, though vulnerability to this risk could not have been predicted in all our patients.
The evidence to support our diagnosis is persuasive. Five of the seven patients complained of severe leg pain yet only two lost a major pulse. An actual or potential source of pre-existing clot was identified in three of these five, and in one who lost a pulse there was definite necropsy evidence of lysis of the clot. Cold, mottled skin without loss of pulses, affecting the lower trunk and legs but sparing the upper body seems to be characteristic and is difficult to explain on other grounds. Our three patients with cerebrovascular accidents developed catastrophic symptoms within hours after treatment. Two had evidence of brain infarction without haemorrhage. The third had evidence of multiple infarcts with a haemorrhage that was probably a secondary event; he also had sudden and typical manifestations of lower body ischaemia with proved pre-existing clot in the left ventricle and the aorta.
With the possible exception of case 7, the events described are unlikely to have resulted from left ventricular thrombus secondary to the infarction. Serial echocardiographic studies have shown that mural thrombus is uncommon in inferior myocardial infarction56 and only rarely develops in the first 72 hours after anterior myocardial infarction.5 Embolic events tend to occur late, and multiple emboli are rare. 6 It is important that in five of our seven cases symptoms occurred within 12 hours after thrombolysis. An. alternative explanation for the widespread effects seen in cases 1, 4, 5, and 6 is a vasculitic reaction. But in no case was the clinical picture typical of the syndrome that we have described previously after treatment with anistreplase,3 although this diagnosis was entertained briefly in one case. The skin, when affected, was mottled, with patchy ischaemia rather than a purpuric rash. Pain was not a feature in our patients with vasculitis. In one case the concentration of circulating immune complexes was increased. As these are not routinely measured after uncomplicated thrombolysis we do not know if this is of any importance.
We are not aware of any reports of microembolic phenomena after the use of anistreplase, although anecdotal reports have associated streptokinase with microscopic evidence of cholesterol emboli.7 The mechanism proposed is that thrombolysis removes thrombus overlying atheromatous plaques, thus allowing cholesterol debris to enter the bloodstream.8 This process may have been responsible for some of the cases reported above, but in others it seems certain that fragments of the lysed clot itself were responsible for the subsequent embolic event. We noted that fibrinogen concentrations were increased in three of five cases in which it was measured whereas thrombolytic agents usually reduce the levels of circulating fibrinogen.9 Hyperfibrinogenaemia was also noted in a previous report of a cerebral embolus after thrombolytic treatment with streptokinase.' This may be a chance finding, but we suggest that fibrinogen should be measured in other similar cases.
The strikingly beneficial effect of iloprost in case 
Introduction
Neuropathological studies in North America and Europe of patients dying ofAIDS have shown a variety of changes, including an encephalopathy or encephalitis associated with multinucleated giant cells in 25-30% of cases.`In addition, there may be lesions due to opportunistic infections or lymphomas. In most of the necropsy series reported most cases of infection with HIV occurred in homosexual men and drug abusers. Haemophiliacs with HIV infection acquired from infected blood products have generally formed a small proportion of the total cases reported, and there has been no clear indication of whether the neuropathology in these subjects differs from that in other groups at risk. We present the results of neuropathological examination at necropsy in a series of subjects infected with HIV that included a fairly high proportion of haemophiliacs (25%).
Subjects and methods
We examined brains from 42 subjects known to have had antibodies to HIV. Eleven were haemophiliacs, 29 were known to have been homosexual, one was the husband of a drug addict, and one was a nurse from Zambia. All but one were men. The mean age of the haemophiliacs was 41 years (range 15-69) and that of the non-haemophiliacs 40 years (21-60). The duration for which the haemophiliacs were known to have had HIV antibodies varied between nine and 48 months (mean 31 months) and for the other subjects from nil to 48 months (mean 15 months). Agreed criteria for the clinical diagnosis of AIDS6 were met in four of the haemophiliacs and in all but one of the other subjects.
